Oncoveda Genesisbiotech Group
Home About Us Collaborations Products Research Publications

Publications

Scientific Journals

Pusey M, Bail S, Xu Y, Buiakova O, Nestor M, Yang J, Rice LM. Inhibition of Protein Methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models. Tumor Biology, Accepted.

Pallai R, Bhaskar A, Barnett-Bernodat N, Gallo-Ebert C, Pusey M, Nickels JT, Rice LM. Leucine Rich Repeat-Containing Protein 59 Mediates Nuclear Import of Cancerous Inhibitor of PP2A in Prostate Cancer Cells. Tumor Biology. 2015; 36(8): 6383 – 6390.

Pallai R, Bhaskar A, Barnett-Bernodat N, Gallo-Ebert C, Nickels JT, Rice LM. Cancerous Inhibitor of Protein Phosphatase 2A Promotes Premature Chromosome Segregation and Aneuploidy in Prostate Cancer Cells through Association with Shugoshin. Tumor Biology. 2015; 36(8): 6067 – 6074.

Pusey M, Bail S, Werda A, Rice LM.  Protein Phosphatsae Methylesterase 1: A potential therapeutic target and companion diagnostic marker for cancer. Cancer Cell & Microenvironment.  2014; 1(5): e299.

Wandzioch E, Pusey M, Werda A, Bail S, Bhaskar A, Nestor M, Yang J, Rice LM. PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells. Cancer Research. 2014 Aug 15; 74(16): 4295 – 4305.

Rice LM, Donigan M, Yang M, Liu W, Pandya D, Joseph B, Sodi V, Gearhart T, Yip J, Bouchard M, and Nickels JT. Protein phosphatase 2A regulates low-density lipoprotein uptake through regulating SREBP-2 DNA binding. J. Biol. Chem. 2014; 289: 17268 – 17279.

Scher MB, Elbaum MB, Mogilevkin Y, Hilbert DW, Mydlo JH, Sidi AA, Adelson ME, Mordechai E, Trama JP. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in u rine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer. J Urol. 2012 Dec; 188(6): 2101 – 7.

Pallai R, Bhaskar A, Sodi V, Rice LM. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription. 2012 Nov. 1; 3(6): 323 – 335.

Huang LP, Savoly D, Sidi AA, Adelson ME, Mordechai E, Trama JP. CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med. 2012 Aug; 1 (1): 76 – 81.

Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA, Trama JP. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer. 2011 Jun 10; 11: 234.

Nolt JK*, Rice LM*, Gallo-Ebert C, Bisher ME, Nickels JT. PP2ACdc55 is required for multiple events during meiosis I. Cell Cycle. 2011 May 1; 10(9): 1420 – 34. (* These authors contributed equally.)

Huang LP, Adelson ME, Mordechai E, Trama JP. CIP2A expression is elevated in cervical cancer. Cancer Biomark. 2010 – 2011; 8(6): 309 – 17.

Martin AG, Trama J, Crighton D, Ryan KM, Fearnhead HO. Activation of p73 and induction of Noxa by DNA damage requires NK-kappa B. Aging (Albany NY). 2009 Feb 18; 1(3):335-49.

Huang LP, Lyu SC, Clayberger C, Krensky AM. Granulysin-mediated tumor rejection in transgenic mice. J Immunol. 2007 Jan 1; 178(1):77-84.

Patents

US Patent No. 9,139,829 “SiRNA Targeting ETS1 and ELK1 and Method of Using Same in the Inhibition of CIP2A Gene in Cancer Treatment.” Rajash Pallai and Lyndi M. Rice. September 22, 2015.

US Patent No. 9,096,905 “Detecting DNA Methylation of BCL2, CDKN2A and NID2 Genes to Predict Bladder Cancer in Humans.” Michael Scher and Jason Trama. August 4, 2015.

US Patent No. 8,741,582 “Detection of a Specific DEK Isoform as a Urine-Based Biomarker for Bladder Cancer.” Antara Datta and Jason Trama. June 3, 2014.

US Patent No. 8,658,376 “DEK as a Urine Based Biomarker for Bladder Cancer.” Antara Datta and Jason Trama. February 25, 2014.

Presentations

Wandzioch E, Pusey M, Werda A, Bhaskar A, Trama JP, Rice LM.  PME-1 Promotes Endometrial Cancer Progression through Inhibition of PP2A. Europhosphatase 2013: Protein Phosphatases in Health and Disease, Rehovot, Israel, July 7 – 12, 2013.

Huang LP, Stemmer SM, Trama JP. CIP2A Expression is a Novel Biomarker for the Detection of Cervical Cancer. American College of Obstetricians and Gynecologists 59th Annual Clinical Meeting, Washington DC, April 30 – May 4, 2011.

Huang LP, Libby EK, Trama JP. Identify and Evaluate Novel Biomarker CIP2A for Cervical Cancer Diagnostics. American Association for Cancer Research 102nd Annual Meeting, Orlando FL, April 2-6, 2011.

Libby EK, Eble SM, Adelson ME, Mordechai E, Trama JP. Separate Functions of Caspase-3 in Cell Migration and Apoptosis. American Association for Cancer Research 101st Annual Meeting, Washington DC, April 17-21, 2010.

Datta A, Adelson ME, Mordechai E, Trama JP. Oncoprotein DEK as a Tissue and Urinary Biomarker for Bladder Cancer. American Association for Cancer Research 101st Annual Meeting, Washington DC, April 17-21, 2010.

Latest News

Updated Website! - The Oncoveda website has been fully updated! Please take a moment to learn about our current programs and scientific members!

Projects for Lab Rotations/Internships within Oncoveda - Please access the Research Page (link above) to learn about the lab rotation/internship projects that are currently available in Oncoveda.

Article Accepted into Tumor Biology - Our article further describing the role of PME-1 in endometrial cancer tumor progression titled "Inhibition of Protein Methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models" has been accepted for publication in Tumor Biology.